Latest:
Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma Treatment
Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Barry Fortner, PhD
Latest:
Community Practice Provides Model for Finding New Revenue in COVID-19 Era
The coronavirus disease 2019 pandemic is highlighting how independent community oncology practices are the best source for patients to receive care close to home, while also presenting several challenges for practices and their patients.
Beata Jagielska, MD, PhD
Latest:
Dr. Jagielska on Long-Term Survival With Lapatinib Plus Capecitabine in HER2+ Breast Cancer
Beata Jagielska, MD, PhD, internist, Centrum Medyczne Damiana Warsaw, discusses long-term survival with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive breast cancer.
Becky Clark, MS, CGC
Latest:
CMS Should Broaden Coverage for Germline Mutation Testing
Sometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.
Ben Leach
Latest:
Immediate Impact Anticipated From Neoadjuvant Pertuzumab
The new indication for pertuzumab (Perjeta) as part of a three-drug neoadjuvant regimen for patients with HER2-positive metastatic breast cancer marks the first time the FDA has authorized a therapy based on pathologic complete response.
Benjamin A. Gartrell, MD
Latest:
Dr. Gartrell on Tolerability of SM-88 in Prostate Cancer
Benjamin A. Gartrell, MD, assistant professor of urology, Albert Einstein College of Medicine, medical oncologist, Montefiore Medical Center, discusses the tolerability of SM-88 in the treatment of patients with prostate cancer.